Immuneel and Arogya Finance Launch Zero Cost EMI for CAR-T Therapy

In a significant development for cancer patients in India, Immuneel and Arogya Finance have launched the country’s first zero cost EMI program specifically for Qartemi® CAR-T cell therapy. This innovative financial initiative allows patients to access treatment worth up to ₹25 lakh without the burden of immediate costs. The zero cost EMI program is designed to make advanced CAR-T cell therapy more accessible to patients battling certain types of blood cancers. With rising healthcare costs, this initiative aims to alleviate financial stress, enabling patients to focus on their recovery rather than their finances. Under this program, eligible patients can avail loans of up to ₹25 lakh. The financing is structured in a way that eliminates interest payments, making it an attractive option for those in need of expensive medical treatment. Immuneel and Arogya Finance have emphasized their commitment to patient welfare and financial inclusivity through this initiative. The introduction of the zero cost EMI program is expected to significantly impact the accessibility of CAR-T therapy in India. With the treatment being one of the most advanced and effective options for certain hematological malignancies, the financial barrier often prevents many patients from seeking it. By providing a structured payment option, Immuneel and Arogya Finance are paving the way for more patients to receive this life-saving treatment. This initiative aligns with the broader goal of improving healthcare accessibility in India, particularly for cutting-edge therapies that can be prohibitively expensive. As the healthcare landscape in India continues to evolve, initiatives like the zero cost EMI program are crucial. They not only provide immediate financial relief but also encourage the adoption of advanced medical treatments. Stakeholders in the healthcare sector are hopeful that such programs will lead to increased awareness and utilization of CAR-T therapies across the country. Immuneel and Arogya Finance’s zero cost EMI program for Qartemi® CAR-T therapy represents a landmark step towards making advanced cancer treatment financially accessible. By removing the cost barrier, they are not only enhancing patient care but also contributing to the overall improvement of the healthcare system in India. Based on reports from Google News — Finance India.